Compare Novartis AG (NVS) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Value Index Fund ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Value Index Fund ETF trades at $218.63. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VTV | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | — |
52-Week High | $168.62 | $220.51 |
52-Week Low | $113.50 | $175.51 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
VTV trades at $218.63, up 0.33% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks, offering diversification with low tech exposure and a 0.03% expense ratio. Recent news highlights its role as a stability play amid AI volatility, with a 16% YTD gain and a 27% one-year advance as of July 2026.
Outlook remains positive due to investor rotation into value stocks and Fed policy sensitivity. Risks include inflation-driven rate hikes and concentrated sector bets. Analyst sentiment favors VTV for defensive positioning, but macroeconomic shifts could challenge momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
